Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "metabolic interactions" wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-2 z 2
    Tytuł:
    Interactions of Some Organic Solvents: Hydrocarbons and Chloroalkene
    Autorzy:
    Skowroń, J.
    Miranowicz-Dzierżawska, K.
    Zapór, L.
    Gołofit-Szymczak, M.
    Starek, A.
    Powiązania:
    https://bibliotekanauki.pl/articles/90439.pdf
    Data publikacji:
    2001
    Wydawca:
    Centralny Instytut Ochrony Pracy
    Tematy:
    n-hexane
    ethylbenzene
    tetrachloroethylene
    metabolic interactions
    toxicodynamic interactions
    interakcje metaboliczne
    tetrachloroetylen
    etylobenzen
    Opis:
    Metabolic and toxicodynamic interactions of some organic solvents in rats repeatedly treated with medium dose levels were examined. It was shown that both n-hexane and ethylbenzene significantly inhibited tetrachloroethylene metabolism during a 2-week period. n-Hexane and tetrachloroethylene enhanced metabolism of ethylbenzene whereas ethylbenzene suppressed n-hexane metabolism only at the end of the experiment. Biochemical changes, especially the drop in the level of non-protein sulfhydryl groups in tissues of rats treated with organic solvent mixtures, were significantly less pronounced than those observed after these chemicals were administered separately. These results demonstrate that metabolic interactions between hydrocarbons and chloroalkene may lead to a modification of the biological response to these compounds.
    Źródło:
    International Journal of Occupational Safety and Ergonomics; 2001, 7, 1; 35-47
    1080-3548
    Pojawia się w:
    International Journal of Occupational Safety and Ergonomics
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    In Vitro approach for identification of a leading cytochrome P450 isoenzyme responsible for biotransformation of novel arylpiperazine drug candidates and their inhibition potency towards CYP3A4.
    Autorzy:
    Ulenberg, Szymon
    Belka, Mariusz
    Georgiev, Paweł
    Król, Marek
    Herold, Franciszek
    Bączek, Tomasz
    Powiązania:
    https://bibliotekanauki.pl/articles/895671.pdf
    Data publikacji:
    2020-02-29
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    cytochrome P-450
    drug-drug interactions
    isoform
    arylpiperazine
    CYP 3A4 inhibitor
    metabolic stability
    Opis:
    Presented article is a follow-up study of previous work, published in PLoS ONE in 2015 regarding metabolic stability of arylpiperazine derivatives, a very promising group of novel antidepressants. The aim of this study was to identify cytochrome P450 (CYP) isoforms that participate in the metabolism of some novel arylpiperazine derivatives developed by authors as well as their potency to inhibit reactions catalysed by identified lead metabolizing enzyme. Such studies allow to predict possible drug-drug interactions that might occur during co-administration of studied compounds with other drugs that are metabolized by identified enzyme. The compounds were incubated in vitro together with the isolated CYP isoforms. After the incubation, samples were analyzed by liquid chromatography coupled with mass spectrometry. The results showed main contribution of CYP3A4 isoform in biotransformation of the investigated derivatives. With CYP3A4 being the main CYP isoform responsible for the metabolism of arylpiperazine derivatives and at the same time being the main metabolizing enzyme for almost 50% of all drugs, a high chance of in vivo drug-drug interactions emerged. Therefore, IC50 values were also determined using testosterone hydroxylation as a probe reaction, specific for CYP3A4. The resulting values ranged from 6.13 to 15.85 µM, which places studied derivatives as moderate or weak inhibitors of CYP3A4. Those results, combined with conclusion that all of the arylpiperazine derivatives are also metabolized to some extent by other CYP isoforms (providing alternative metabolic pathways), result in conclusion that studied arylpiperazines might be safe for co-administration with other CYP3A4 substrates.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 1; 69-76
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-2 z 2

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies